abstract: BACKGROUND AND OBJECTIVE: @entity1 ( @entity1 ) is a chronic @entity2 that affects the central nervous system. Researchers have looked for an association between @entity3 ( @entity3 ) and human leukocyte antigen (HLA) as risk or protective factor associated to ethnicity, which may add a partial explanation to disease heterogeneity and geographical variations. We described the frequency of the HLA-DR alleles in Mexican Mestizo ( @entity3 ) @entity0 . @entity0 AND METHODS: We included 143 @entity3 @entity0 and 377 healthy controls, both Mexican Mestizos. Previous signing informed consent, we record demographic and clinical characteristics of the @entity0 . Genetic profile was made, and HLA frequencies in both groups were compared. RESULTS: @entity3 @entity0 were 39.8% male and 60.2% female, mean age was 35 years. While, controls were 48%male and 52% @entity0 , mean age was 38 years. The most frequent allele found in subjects with @entity3 was DR 15 (p=0.006, OR=2.2, 95% CI: 1.3-3.6). DR 13 allele was more frequent among healthy subjects than @entity3 @entity0 (p=0.050) with a protective OR 2.6, (95% CI: 1.3-5.2, p=0.050). CONCLUSION: In our study we found HLA DR 13 was more frequent in healthy controls than in @entity3 @entity0 , suggesting a protective factor among Mexican Mestizo population.

title: Presence of the HLADR13 allele among Mexican Mestizos suggests a protective factor against relapsing-remitting @entity1 ( XXXX ).

answer: @entity3


abstract: CONTEXT: Wrist @entity2 are common among postmenopausal @entity0 . Associations of @entity1 ( @entity1 ) and 10-year predicted risk of @entity3 ( @entity3 ) with wrist @entity2 are poorly characterized. OBJECTIVE: The objective was to examine associations between the Fracture Risk Assessment Tool (FRAX)-predicted risk of @entity3 , @entity1 , @entity1 change, and wrist @entity2 . DESIGN: This was a prospective observational study with a mean follow-up of 8.5 years. SETTING: This study included 40 @entity4 centers. @entity0 : A total of 11 392 @entity0 from the @entity0 's Health Initiative @entity1 Cohort aged 50-79 years at baseline were included in this study. INTERVENTIONS: None. MAIN OUTCOME: The goal was to measure incident wrist @entity2 . RESULTS: A FRAX-predicted @entity3 risk >= 9.3% identified 17% of the @entity0 aged <65 years who subsequently experienced wrist @entity2 . Each one standard deviation lower @entity1 was associated with higher wrist @entity2 risk, with adjusted hazard ratio (95% confidence interval) of 1.66 (1.42-1.93) for femoral neck (FN) @entity1 and 1.45 (1.28-1.64) for lumbar spine @entity1 . Compared with FN @entity1 T score >=  -1.0, wrist @entity2 adjusted hazard ratios (95% confidence interval) were: 1.51 (1.06-2.16) for a T score between -1.01 and -1.49; 1.93 (1.36-2.72) for T score between -1.50 and -1.99; 2.52 (1.77-3.60) for a T score between -2.00 and -2.49; and 2.65 (1.78-3.95) for a T score  <= -2.5. Decrease in FN @entity1 between baseline and year 3 was associated with increased risk of subsequent wrist @entity2 ; however, change in lumbar spine @entity1 was not. CONCLUSIONS: Lumbar spine and femoral neck BMDs were associated with incident wrist @entity2 , but the FRAX threshold recommended to identify screening candidates did not identify the majority of @entity0 who subsequently experienced wrist @entity2 . Improved understanding of determinants of wrist @entity2 is warranted.

title: Bone Mineral Density as a Predictor of Subsequent Wrist Fractures: Findings From the XXXX 's Health Initiative Study.

answer: @entity0


abstract: PURPOSE: @entity2 surveillance guidelines do not routinely include positron emission tomography (PET) imaging; however, its use after surgical resection has been increasing. We evaluated the secular patterns of PET use after surgical resection of @entity2 among elderly @entity0 and identified factors associated with its increasing use. @entity0 AND METHODS: We used the SEER-linked Medicare database (July 2001 through December 2009) to establish a retrospective cohort of @entity0 age >=  66 years who had undergone surgical resection for @entity2 . Postoperative PET use was assessed with the test for trends. @entity0 , @entity1 , and treatment characteristics were analyzed using univariable and multivariable logistic regression analyses. RESULTS: Of the 39,221 @entity0 with @entity2 , 6,326 (16.1%) had undergone a PET scan within 2 years after surgery. The use rate steadily increased over time. The majority of PET scans had been performed within 2 months after surgery. Among @entity0 who had undergone a PET scan, 3,644 (57.6%) had also undergone preoperative imaging, and 1,977 (54.3%) of these @entity0 had undergone reimaging with PET within 2 months after surgery. Marriage, year of diagnosis, @entity1 stage, preoperative imaging, postoperative visit to a medical oncologist, and adjuvant chemotherapy were significantly associated with increased PET use. CONCLUSION: PET use after @entity2 resection is steadily increasing, and further study is needed to understand the clinical value and effectiveness of PET scans and the reasons for this departure from guideline-concordant care.

title: Variation in positron emission tomography use after XXXX resection.

answer: @entity2


abstract: There is evidence that @entity7 used routinely in the fixation process of bioprosthetic heart valves may be a major factor in their subsequent @entity5 . A further complication is introduced by the use of a @entity3 treatment step, whether for sterilization or storage. The effects of this second @entity1 on @entity5 is also unknown. The aim of the present work is to determine the degree of @entity7 and @entity3 incorporation into commercial valve leaflets and to establish whether there is a relationship between the @entity1 treatment and tissue @entity5 . Both pre- and post-implantation concentrations of @entity6 were estimated by high performance liquid chromatography of acid hydrolyzates of commercial valve tissue. Control samples were taken from freshly prepared porcine aortic valves and @entity2 pericardium fixed in @entity7 . The degree of @entity5 was investigated using the @entity0 subcutaneous implant model. Samples were retrieved after 56 days and @entity4 estimated by atomic absorption spectroscopy. The results indicated that storage of both porcine and pericardial valves for periods of 5 years or longer reduced @entity5 . A greater reduction in @entity5 was noted when tissue was treated sequentially with @entity7 and @entity3 rather than @entity7 alone. From this work it can be concluded that bioprosthetic valves calcify less in the @entity0 model when they are stored for extended periods of time in @entity7 solution. This effect is enhanced when @entity3 storage is employed.

title: Acid hydrolyzable XXXX in long-term stored commercial bioprosthetic heart valves implications for @entity5 .

answer: @entity6


abstract: There is evidence that @entity7 used routinely in the fixation process of bioprosthetic heart valves may be a major factor in their subsequent @entity5 . A further complication is introduced by the use of a @entity3 treatment step, whether for sterilization or storage. The effects of this second @entity1 on @entity5 is also unknown. The aim of the present work is to determine the degree of @entity7 and @entity3 incorporation into commercial valve leaflets and to establish whether there is a relationship between the @entity1 treatment and tissue @entity5 . Both pre- and post-implantation concentrations of @entity6 were estimated by high performance liquid chromatography of acid hydrolyzates of commercial valve tissue. Control samples were taken from freshly prepared porcine aortic valves and @entity2 pericardium fixed in @entity7 . The degree of @entity5 was investigated using the @entity0 subcutaneous implant model. Samples were retrieved after 56 days and @entity4 estimated by atomic absorption spectroscopy. The results indicated that storage of both porcine and pericardial valves for periods of 5 years or longer reduced @entity5 . A greater reduction in @entity5 was noted when tissue was treated sequentially with @entity7 and @entity3 rather than @entity7 alone. From this work it can be concluded that bioprosthetic valves calcify less in the @entity0 model when they are stored for extended periods of time in @entity7 solution. This effect is enhanced when @entity3 storage is employed.

title: Acid hydrolyzable @entity6 in long-term stored commercial bioprosthetic heart valves implications for XXXX .

answer: @entity5


abstract: OBJECTIVES: The @entity3 / @entity2 combination for the treatment of @entity4 is available in a film or tablet formulation. Recent retrospective studies demonstrated that treatment with the sublingual film formulation is associated with improved treatment retention and lower healthcare costs. In March 2013, generic @entity3 / @entity2 tablets were approved in the US. A budget impact model was built to compare healthcare expenditures for different market shares of sublingual film and tablet. METHODS: A Markov model was developed to track a cohort of opioid dependent @entity0 treated with sublingual film or tablet through the following treatment phases: initiation, maintenance, discontinuation, off-treatment and reinitiation. Transition probabilities and costs for each phase were estimated from the MarketScan Medicaid database for the period between 1 March 2010 and 30 June 2012. The total expenditure for the plan and expenditure per plan member per month were predicted over 5 years. Two market share scenarios were considered: 1) sublingual film is progressively replaced by generic tablet (current situation) and 2) the sublingual film holds a market share of 100%. RESULTS: Predicted total costs over 5 years were  6400 million when the sublingual film holds a market share of 100% (as per Scenario 2) which is lower than when sublingual film is progressively replaced by generic tablet (current situation as per Scenario 1) by  64 million. These savings were mostly driven by inpatient care ( 56 million saved over 5 years), followed by emergency room care ( 27 million) and pharmaceutical costs ( 24 million). Costs of outpatient care attenuated the difference as they were predicted to be higher by  44 million in Scenario 2. The reduction in total cost per member per month reached  0.027 in the fifth year. Results were most sensitive to price rebates and to the probability of non- @entity1 hospitalization. CONCLUSIONS: While using the sublingual film formulation for more @entity0 treated with @entity3 / @entity2 is predicted to increase outpatient care costs, it would generate savings in emergency care and hospitalizations. In the treatment of @entity4 , total direct medical costs for Medicaid would be lower for sublingual film treated @entity0 , at current drug prices.

title: Budgetary impact of the utilization of @entity3 / XXXX sublingual film and tablet for Medicaid in the United States.

answer: @entity2


abstract: OBJECTIVES: The @entity3 / @entity2 combination for the treatment of @entity4 is available in a film or tablet formulation. Recent retrospective studies demonstrated that treatment with the sublingual film formulation is associated with improved treatment retention and lower healthcare costs. In March 2013, generic @entity3 / @entity2 tablets were approved in the US. A budget impact model was built to compare healthcare expenditures for different market shares of sublingual film and tablet. METHODS: A Markov model was developed to track a cohort of opioid dependent @entity0 treated with sublingual film or tablet through the following treatment phases: initiation, maintenance, discontinuation, off-treatment and reinitiation. Transition probabilities and costs for each phase were estimated from the MarketScan Medicaid database for the period between 1 March 2010 and 30 June 2012. The total expenditure for the plan and expenditure per plan member per month were predicted over 5 years. Two market share scenarios were considered: 1) sublingual film is progressively replaced by generic tablet (current situation) and 2) the sublingual film holds a market share of 100%. RESULTS: Predicted total costs over 5 years were  6400 million when the sublingual film holds a market share of 100% (as per Scenario 2) which is lower than when sublingual film is progressively replaced by generic tablet (current situation as per Scenario 1) by  64 million. These savings were mostly driven by inpatient care ( 56 million saved over 5 years), followed by emergency room care ( 27 million) and pharmaceutical costs ( 24 million). Costs of outpatient care attenuated the difference as they were predicted to be higher by  44 million in Scenario 2. The reduction in total cost per member per month reached  0.027 in the fifth year. Results were most sensitive to price rebates and to the probability of non- @entity1 hospitalization. CONCLUSIONS: While using the sublingual film formulation for more @entity0 treated with @entity3 / @entity2 is predicted to increase outpatient care costs, it would generate savings in emergency care and hospitalizations. In the treatment of @entity4 , total direct medical costs for Medicaid would be lower for sublingual film treated @entity0 , at current drug prices.

title: Budgetary impact of the utilization of XXXX / @entity2 sublingual film and tablet for Medicaid in the United States.

answer: @entity3


abstract: @entity4 supplements, but not dietary @entity4 , have been associated with increased cardiovascular risk. This difference could be related to differences in their acute effects on serum @entity4 . We therefore examined the effects of @entity4 from different sources on serum @entity4 and @entity3 in a randomised, cross-over trial of ten @entity0 (mean age of 69 years). Fasting @entity0 received a single dose of 500 mg of @entity4 as @entity2 , @entity2 with a meal, fortified juice or a dairy product meal, with at least 6 d between each intervention. Blood was sampled before and 1, 2, 4 and 6 h after each intervention was ingested. Serum ionised and total @entity4 increased significantly from baseline over 6 h. Using @entity5 fasting as a comparator, the elevations in ionised and total @entity4 were similar after fortified juice, delayed after @entity5 with a meal and smaller after a dairy product meal. Serum @entity3 and @entity1 product increased from baseline after @entity5 with a meal and after a dairy product meal, and they declined after @entity5 fasting and after fortified juice. The elevations in serum @entity4 in the present study were only slightly different from those observed after the administration of 1000 mg of @entity4 in a previous study. These data indicate that different sources of @entity4 have different acute effects on serum @entity4 and support recommendations that dietary @entity4 might be safer than supplements. Whether these differences contribute to differences in cardiovascular risk requires further study.

title: Acute effects of @entity5 with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and XXXX : a randomised cross-over trial.

answer: @entity3


abstract: @entity4 supplements, but not dietary @entity4 , have been associated with increased cardiovascular risk. This difference could be related to differences in their acute effects on serum @entity4 . We therefore examined the effects of @entity4 from different sources on serum @entity4 and @entity3 in a randomised, cross-over trial of ten @entity0 (mean age of 69 years). Fasting @entity0 received a single dose of 500 mg of @entity4 as @entity2 , @entity2 with a meal, fortified juice or a dairy product meal, with at least 6 d between each intervention. Blood was sampled before and 1, 2, 4 and 6 h after each intervention was ingested. Serum ionised and total @entity4 increased significantly from baseline over 6 h. Using @entity5 fasting as a comparator, the elevations in ionised and total @entity4 were similar after fortified juice, delayed after @entity5 with a meal and smaller after a dairy product meal. Serum @entity3 and @entity1 product increased from baseline after @entity5 with a meal and after a dairy product meal, and they declined after @entity5 fasting and after fortified juice. The elevations in serum @entity4 in the present study were only slightly different from those observed after the administration of 1000 mg of @entity4 in a previous study. These data indicate that different sources of @entity4 have different acute effects on serum @entity4 and support recommendations that dietary @entity4 might be safer than supplements. Whether these differences contribute to differences in cardiovascular risk requires further study.

title: Acute effects of XXXX with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and @entity3 : a randomised cross-over trial.

answer: @entity5


abstract: BACKGROUND: Ambulatory @entity0 with @entity2 ( @entity2 ) often present with multiple deviations in all planes including increased internal hip rotation during gait. @entity3 is a common cause of deviation managed surgically with an external @entity3 ( @entity3 ). The purpose of this study was to evaluate the gait and functional outcomes of a group of subjects with @entity2 who underwent surgical intervention that included an @entity3 compared with a match group with indications of internal hip rotation that did not receive an @entity3 . METHODS: For this retrospective study, subjects were identified from the Motion Analysis Laboratory database that had orthopaedic surgery including an @entity3 ( @entity3 group). A control group was established from a chart review identifying subjects that had indications for an @entity3 , but did not have this surgery (No- @entity3 group). All subjects had preoperative and postoperative gait studies. Subjects categorized as Gross Motor Function Classification System (GMFCS) levels I and II in both @entity3 and No- @entity3 groups were combined for analysis. Subjects rated as GMFCS level III were analyzed separately. Preoperative to postoperative kinematic and kinetic variables, Gait Deviation Index, net @entity1 cost, and PODCI scores were analyzed with paired t tests. RESULTS: Typical sagittal plane kinematic variables improved significantly by equivalent magnitudes for both @entity3 and No- @entity3 groups (GMFCS I/II and III). Transverse plane improvements were only seen for the @entity3 group (GMFCS I/II and III). The Gait Deviation Index, an overall index of kinematics, improved by a significantly greater amount for the @entity3 group across GMFCS levels I/II and III. Net @entity1 cost improved for both @entity3 and No- @entity3 for GMFCS I/II. PODCI scores improved for @entity3 and No- @entity3 in GMFCS I/II, but only the @entity3 group for GMFCS III. CONCLUSIONS: For @entity0 with @entity2 , inclusion of an @entity3 in the surgical intervention, when indicated, resulted in improved outcomes. Overall gait kinematic improvements were significantly greater when an @entity3 was included in the surgical management. LEVEL OF EVIDENCE: Level III-retrospective comparative study.

title: Outcomes of Orthopaedic Surgery With and Without an External Femoral Derotational Osteotomy in @entity0 With XXXX .

answer: @entity2


abstract: BACKGROUND: Ambulatory @entity0 with @entity2 ( @entity2 ) often present with multiple deviations in all planes including increased internal hip rotation during gait. @entity3 is a common cause of deviation managed surgically with an external @entity3 ( @entity3 ). The purpose of this study was to evaluate the gait and functional outcomes of a group of subjects with @entity2 who underwent surgical intervention that included an @entity3 compared with a match group with indications of internal hip rotation that did not receive an @entity3 . METHODS: For this retrospective study, subjects were identified from the Motion Analysis Laboratory database that had orthopaedic surgery including an @entity3 ( @entity3 group). A control group was established from a chart review identifying subjects that had indications for an @entity3 , but did not have this surgery (No- @entity3 group). All subjects had preoperative and postoperative gait studies. Subjects categorized as Gross Motor Function Classification System (GMFCS) levels I and II in both @entity3 and No- @entity3 groups were combined for analysis. Subjects rated as GMFCS level III were analyzed separately. Preoperative to postoperative kinematic and kinetic variables, Gait Deviation Index, net @entity1 cost, and PODCI scores were analyzed with paired t tests. RESULTS: Typical sagittal plane kinematic variables improved significantly by equivalent magnitudes for both @entity3 and No- @entity3 groups (GMFCS I/II and III). Transverse plane improvements were only seen for the @entity3 group (GMFCS I/II and III). The Gait Deviation Index, an overall index of kinematics, improved by a significantly greater amount for the @entity3 group across GMFCS levels I/II and III. Net @entity1 cost improved for both @entity3 and No- @entity3 for GMFCS I/II. PODCI scores improved for @entity3 and No- @entity3 in GMFCS I/II, but only the @entity3 group for GMFCS III. CONCLUSIONS: For @entity0 with @entity2 , inclusion of an @entity3 in the surgical intervention, when indicated, resulted in improved outcomes. Overall gait kinematic improvements were significantly greater when an @entity3 was included in the surgical management. LEVEL OF EVIDENCE: Level III-retrospective comparative study.

title: Outcomes of Orthopaedic Surgery With and Without an External Femoral Derotational Osteotomy in XXXX With @entity2 .

answer: @entity0


abstract: BACKGROUND: Immigration from regions with a high incidence of @entity0 ( @entity0 ) has slowed the decline of @entity0 in low-incidence regions. Targeted screening of new immigrants and treatment for @entity2 ( @entity2 ) is needed to reinvigorate this decline. This meta-analysis compares @entity2 diagnostic tests by positive test prevalence and proportion of positive tests by @entity0 incidence. METHODS: A systematic literature search was performed and data extracted based on tuberculin skin test (TST) and/or @entity1 release assay (IGRA) use in immigrants. For the eight studies performing tests concurrently, data were compared by positive tests and concordance, while other studies comparing individual tests were analyzed based on demographic factors. Data were analyzed via meta-analysis. RESULTS: Forty-five studies with a combined sample size of 93,249 individuals were included in the analyses, 2206 of which were from the eight concurrent studies. Odds of a positive TST were significantly higher than an IGRA (odds ratio 1.46; 95  % confidence interval 1.07-2.01) and test agreement was moderate. Proportion of positive TST and IGRA tests increased with @entity0 incidence, although not linearly. CONCLUSION: TST and IGRA data relating to immigrants are lacking, especially long-term follow-up and comparative data. Further data are urgently needed to determine @entity0 risks after immigration, long-term @entity0 development, and treatment outcomes.

title: XXXX Infection Screening in Immigrants to Low-Incidence Countries: A Meta-Analysis.

answer: @entity2


abstract: In order to assess pharmacokinetic differences between @entity5 (S) and @entity3 (P), two @entity1 derivatives, 24 in- @entity0 , 12 males and 12 females mean age 59.4 years, suffering from recurrent @entity2 were enrolled. @entity0 were randomly allocated to S (12 @entity0 ) and to P (12 @entity0 ) and were given 2 g i.m. every 12 h of the awarded antibiotic, for a 7-day period. At the first and 7th day blood samples (0.25, 0.5, 1, 2, 4, 6, 8 and 12 h after dosing) as well as sputum samples (1, 2, 4, 8, 12 h after dosing) and urine samples (3, 6, 9 and 12 h after dosing) were collected, and the levels of S or P were determined by @entity4 test. The pharmacokinetic analysis was performed by a standard program. On day 1 and 7 the mean peak serum concentration occurred at the first hour for S (39.9 +/- 5.2; 40.9 +/- 5.1 mcg/ml, respectively) and for P (32.2 +/- 5.4; 33.1 +/- 5.4 mcg/ml, respectively). Serum AUC0-12 and AUC0-00 (mg/l.h) levels of S were significantly higher (p less than 0.01 or less) than those of P on day 1 and 7. Similarly MRT (8 h) and Cmax (mg/l) where higher but only on day 7. Sputum AUC0-12 (mg/l.h) level of S was significantly higher (p less than 0.05) than that of P on day 1 and 7. In conclusion serum and sputum S appear to have a different pharmacokinetic profile in respect to P. However, when compared to the AUC, both drugs reach antibacterial levels.

title: Comparison between @entity5 and XXXX levels in serum and in bronchial secretions--a pharmacokinetic study.

answer: @entity3


abstract: In order to assess pharmacokinetic differences between @entity5 (S) and @entity3 (P), two @entity1 derivatives, 24 in- @entity0 , 12 males and 12 females mean age 59.4 years, suffering from recurrent @entity2 were enrolled. @entity0 were randomly allocated to S (12 @entity0 ) and to P (12 @entity0 ) and were given 2 g i.m. every 12 h of the awarded antibiotic, for a 7-day period. At the first and 7th day blood samples (0.25, 0.5, 1, 2, 4, 6, 8 and 12 h after dosing) as well as sputum samples (1, 2, 4, 8, 12 h after dosing) and urine samples (3, 6, 9 and 12 h after dosing) were collected, and the levels of S or P were determined by @entity4 test. The pharmacokinetic analysis was performed by a standard program. On day 1 and 7 the mean peak serum concentration occurred at the first hour for S (39.9 +/- 5.2; 40.9 +/- 5.1 mcg/ml, respectively) and for P (32.2 +/- 5.4; 33.1 +/- 5.4 mcg/ml, respectively). Serum AUC0-12 and AUC0-00 (mg/l.h) levels of S were significantly higher (p less than 0.01 or less) than those of P on day 1 and 7. Similarly MRT (8 h) and Cmax (mg/l) where higher but only on day 7. Sputum AUC0-12 (mg/l.h) level of S was significantly higher (p less than 0.05) than that of P on day 1 and 7. In conclusion serum and sputum S appear to have a different pharmacokinetic profile in respect to P. However, when compared to the AUC, both drugs reach antibacterial levels.

title: Comparison between XXXX and @entity3 levels in serum and in bronchial secretions--a pharmacokinetic study.

answer: @entity5


abstract: PURPOSE: To compare the accuracy of different MR sequences in simultaneous PET/MR imaging for T staging in @entity2 in relation to histopathology. METHODS: The study included 28 @entity0 who underwent dedicated thoracic PET/MR imaging before @entity1 resection. Local @entity1 staging was performed separately by three readers with each of the following MR sequences together with PET: transverse T2 BLADE, transverse non-enhanced and contrast-enhanced T1 FLASH, T1 3D Dixon VIBE in transverse and coronal orientation, coronal T2 HASTE, and coronal TrueFISP. The staging results were compared with histopathology after resection as the reference standard. Differences in the accuracy of T staging among the MR sequences were evaluated using McNemar's test. Due to multiple testing, Bonferroni correction was applied to prevent accumulation of a errors; p   <   0.0024 was considered statistically significant. RESULTS: Compared with histopathology, T-staging accuracy was 69  % with T2 BLADE, 68  % with T2 HASTE, 59  % with contrast-enhanced T1 FLASH, 57  % with TrueFISP, 50  % with non-enhanced T1 FLASH, and 45  % and 48  % with T1 3D Dixon VIBE in transverse and coronal orientation, respectively. Staging accuracy with T2 BLADE was significantly higher than with non-enhanced T1 FLASH and with T1 3D Dixon VIBE in transverse and coronal orientations (p   <   0.0024). T2 HASTE had a significantly higher T-staging accuracy than transverse T1 3D-Dixon-VIBE (p   <   0.0024). CONCLUSION: Transverse T2 BLADE images provide the highest accuracy for @entity1 staging and should therefore be included in dedicated thoracic PET/MR protocols. As T1 3D Dixon VIBE images acquired for attenuation correction performed significantly worse, this sequence cannot be considered sufficiently accurate for @entity1 staging in the thorax.

title: Thoracic staging of XXXX using integrated (18)F-FDG PET/MR imaging: diagnostic value of different MR sequences.

answer: @entity2


abstract: In the past we have shown that @entity0 with @entity2 ( @entity2 ) on hemodialysis show evidence of @entity4 of fat. The present study was designed to verify this finding in an animal model. Male @entity1 weighing +/- 200 g were studied. @entity5 ( @entity5 ) was induced by 2-stage subtotal (5/6) nephrectomy. Control (C) animals were sham-operated. Fat absorption was studied after 6 weeks of @entity5 with the oral fat loading test. Twenty percent intralipid (0.25 g/100 gBW) was given by gastric tube feeding to fasting animals and the appearance of chylomicrons (CHYL) and the rise of @entity3 (TG) in the serum was followed for 5 hrs. In order to isolate the effect of fat absorption, an additional group of @entity5 and C animals was pretreated with @entity6 and triton, thus blocking hepatic TG synthesis and neutralizing peripheral lipoprotein lipase activity. The absorption of CHYL was significantly (p less than 0.01) impaired in all @entity5 animals and averaged 43 and 70 percent of that of the C animals, 1 and 2 hrs after the load respectively. The rise in serum TG did not differ from C in mildly @entity5 animals (Scr 1.0 +/- 0.04). In the more severely uremic animals (Scr 2.6 +/- 0.2), however, pretreated with @entity6 and triton, the rise in serum TG was far less (p less than 0.01) than in C animals (111 +/- 26-903 +/- @entity7 % V.780 +/- 170-5032 +/- @entity8 %) 1 and 5 hrs after the load.(ABSTRACT TRUNCATED AT 250 WORDS)

title: XXXX in the uremic @entity1 .

answer: @entity4


abstract: In the past we have shown that @entity0 with @entity2 ( @entity2 ) on hemodialysis show evidence of @entity4 of fat. The present study was designed to verify this finding in an animal model. Male @entity1 weighing +/- 200 g were studied. @entity5 ( @entity5 ) was induced by 2-stage subtotal (5/6) nephrectomy. Control (C) animals were sham-operated. Fat absorption was studied after 6 weeks of @entity5 with the oral fat loading test. Twenty percent intralipid (0.25 g/100 gBW) was given by gastric tube feeding to fasting animals and the appearance of chylomicrons (CHYL) and the rise of @entity3 (TG) in the serum was followed for 5 hrs. In order to isolate the effect of fat absorption, an additional group of @entity5 and C animals was pretreated with @entity6 and triton, thus blocking hepatic TG synthesis and neutralizing peripheral lipoprotein lipase activity. The absorption of CHYL was significantly (p less than 0.01) impaired in all @entity5 animals and averaged 43 and 70 percent of that of the C animals, 1 and 2 hrs after the load respectively. The rise in serum TG did not differ from C in mildly @entity5 animals (Scr 1.0 +/- 0.04). In the more severely uremic animals (Scr 2.6 +/- 0.2), however, pretreated with @entity6 and triton, the rise in serum TG was far less (p less than 0.01) than in C animals (111 +/- 26-903 +/- @entity7 % V.780 +/- 170-5032 +/- @entity8 %) 1 and 5 hrs after the load.(ABSTRACT TRUNCATED AT 250 WORDS)

title: @entity4 in the uremic XXXX .

answer: @entity1


abstract: BACKGROUND: To assess the possible association between @entity4 treatment and the subsequent risk of @entity3 in @entity1 with @entity0 , a population-based cohort study was conducted using the Taiwanese National Health Insurance Research Database. METHODS: The study cohort contained 24   197 @entity1 diagnosed with @entity0 between 1 January 2000 and 31 December 2004. Among them, 16   556 cases received @entity4 treatment and 7641 did not. Four @entity1 without @entity0 were frequency matched to each case by age and index-year as the @entity2 -free group. The outcome of the analysis of is @entity3 . Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariate Cox proportional hazards regression models. RESULTS: @entity1 with @entity0 exhibited a similar risk of developing @entity3 (adjusted HR   =   0.95, 95% CI   =   0.86-1.04) compared with the @entity2 -free group. In addition, among @entity1 diagnosed with @entity0 , @entity4 users exhibited a significant 17% lower risk of @entity3 compared with those not using @entity4 (adjusted HR   =   0.83, 95% CI   =   0.69-0.98), but the significant difference was limited to 5 years or more use (adjusted HR   =   0.47, 95% CI   =   0.32-0.69). Both @entity4 and aromatase inhibitor use had a joint effect, with a significantly lower risk of @entity3 among @entity1 . CONCLUSION: The results of this population-based cohort study suggest that long-term use of @entity4 in @entity1 with @entity0 is associated with a lower risk of @entity3 .

title: Long-term use of XXXX reduces the risk of @entity3 : a nationwide population-based cohort study.

answer: @entity4


abstract: BACKGROUND: To assess the possible association between @entity4 treatment and the subsequent risk of @entity3 in @entity1 with @entity0 , a population-based cohort study was conducted using the Taiwanese National Health Insurance Research Database. METHODS: The study cohort contained 24   197 @entity1 diagnosed with @entity0 between 1 January 2000 and 31 December 2004. Among them, 16   556 cases received @entity4 treatment and 7641 did not. Four @entity1 without @entity0 were frequency matched to each case by age and index-year as the @entity2 -free group. The outcome of the analysis of is @entity3 . Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariate Cox proportional hazards regression models. RESULTS: @entity1 with @entity0 exhibited a similar risk of developing @entity3 (adjusted HR   =   0.95, 95% CI   =   0.86-1.04) compared with the @entity2 -free group. In addition, among @entity1 diagnosed with @entity0 , @entity4 users exhibited a significant 17% lower risk of @entity3 compared with those not using @entity4 (adjusted HR   =   0.83, 95% CI   =   0.69-0.98), but the significant difference was limited to 5 years or more use (adjusted HR   =   0.47, 95% CI   =   0.32-0.69). Both @entity4 and aromatase inhibitor use had a joint effect, with a significantly lower risk of @entity3 among @entity1 . CONCLUSION: The results of this population-based cohort study suggest that long-term use of @entity4 in @entity1 with @entity0 is associated with a lower risk of @entity3 .

title: Long-term use of @entity4 reduces the risk of XXXX : a nationwide population-based cohort study.

answer: @entity3


abstract: UNASSIGNED: A precursor microRNA (miRNA) has two arms: miR-5p and miR-3p (miR-5p/-3p). Depending on the tissue or cell types, both arms can become functional. However, little is known about their coregulatory mechanisms during the tumorigenic process. Here, by using the large-scale miRNA expression profiles of five @entity1 types, we revealed that several of miR-5p/-3p arms were concordantly dysregulated in each @entity1 . To explore possible coregulatory mechanisms of concordantly dysregulated miR-5p/-3p pairs, we developed a robust computational framework and applied it to @entity0 data. The framework deciphers miR-5p/-3p coregulated protein interaction networks critical to @entity0 development. As a novel part in the method, we uniquely applied the second-order partial correlation to minimize false-positive regulations. Using 279 matched miRNA and mRNA expression profiles extracted from @entity1 and normal lung tissue samples, we identified 17 aberrantly expressed miR-5p/-3p pairs that potentially modulate the gene expression of 35 protein complexes. Functional analyses revealed that these complexes are associated with @entity1 -related biological processes, suggesting the oncogenic potential of the reported miR-5p/-3p pairs. Specifically, we revealed that the reduced expression of @entity2 -5p/-3p pair potentially contributes to elevated expression of genes in the " @entity3 transcription factor network" pathway, which may consequently lead to uncontrolled cell proliferation. Subsequently, the regulation of @entity2 -5p/-3p in the @entity3 signaling pathway was validated by a cohort of 104 matched miRNA and protein (reverse-phase protein array) expression profiles in @entity0 . In summary, our computational framework provides a novel tool to study miR-5p/-3p coregulatory mechanisms in @entity1 .

title: Concordant dysregulation of miR-5p and miR-3p arms of the same precursor microRNA may be a mechanism in inducing cell proliferation and tumorigenesis: a XXXX study.

answer: @entity0


abstract: BACKGROUND: Caregiver burden is an important issue that needs to be addressed when developing management programs for @entity0 with chronic mental illnesses, but there is, as yet, no reliable way for assessing this in China. AIM: Assess the validity and reliability of a brief adapted Chinese version of the Family Experience Interview Schedule (FEIS) among caregivers of inpatients with @entity1 in China. METHODS: We first translated and back-translated the original 114-item FEIS and administered it to 606 primary caregivers of @entity1 inpatients. After excluding 9 items about sociodemographic variables and 9 items that over 15% of respondents were unable to answer, we conducted an exploratory factor analysis using a random half of the sample on the remaining 96 items and, based on the results of the factor analysis, selected the items to be included in the final shortened scale. Correlation analysis, confirmatory factor analysis, and internal consistency measures were used to assess the reliability and validity of the final scale using data from the second half of the sample. RESULTS: The final scale included 28 items that loaded on five dimensions: (a) @entity0 ' violent behavior; (b) @entity0 ' suicidal tendency; (c) caregivers' @entity3 and @entity2 ; (d) disruption of caregivers' daily routines; and (e) caregivers' satisfaction with health services. These five dimensions explained 50.5% of the total variance. Confirmatory factor analysis found reasonable fit of this 5-factor model (   (2) /df=2.94, p<0.001, goodness-of-fit index [GFI]=0.85, comparative fit index [CFI]=0.85, root-mean-square error of approximation [RMSEA]=0.08). The correlation coefficients between each item and the corresponding factor were all above 0.5. The Cronbach a coefficient of the entire scale was 0.76 and that for the five dimensions varied between 0.71 and 0.84. CONCLUSION: The five dimensions of family burden assessed by the 28-item brief Chinese version of FEIS have good internal consistency and, thus, appear to assess valid dimensions of family burden in Chinese caregivers of @entity0 with serious mental illnesses. Further work is needed to assess the test-retest reliability of this scale and its sensitivity to change over time.

title: Brief Chinese version of the Family Experience Interview Schedule to assess caregiver burden of family members of individuals with XXXX .

answer: @entity1


abstract: AIM: To investigate transarterial chemoembolization (TACE) with hepatic infusion of @entity4 and @entity8 and @entity11 chemoembolization in large @entity1 ( @entity1 ). METHODS: In this retrospective study, 132 @entity0 with unresectable HCCs larger than 10 cm were treated with hepatic infusion of @entity4 and @entity8 followed by @entity11 chemoembolization. The primary endpoint was @entity7 ( @entity7 ). Sixteen-week disease-control rate, @entity5 ( @entity5 ), and major complications were also studied. Univariate and multivariate analyses were performed to identify prognostic factors affecting @entity7 and @entity5 . RESULTS: A total of 319 procedures were performed in the 132 @entity0 . Eleven (8.3%) @entity0 received radical resection following TACE treatment (median time to initial TACE 4.3    2.3 mo). The median @entity7 and @entity5 were 10.3 and 3.0 mo respectively, with a 50.0% 16-wk disease-control rate. Major complications were encountered in 6.0% (8/132) of @entity0 following TACE and included serious @entity6 in 1.5% (2/132) @entity0 , @entity10 in 1.5% (2/132), and @entity9 in 3.0% (4/132). One @entity0 died within one month due to serious @entity9 and @entity3 after receiving the second TACE. The risk factor associated with @entity5 was baseline @entity2 level, and vascular invasion was an independent factor related to @entity7 . CONCLUSION: Hepatic infusion of @entity4 and @entity8 followed by lipiodolized-chemoembolization is a safe and promising treatment for @entity0 with HCCs larger than 10 cm in diameter.

title: XXXX and @entity8 hepatic infusion with lipiodolized chemoembolization in large @entity1 .

answer: @entity4


abstract: AIM: To investigate transarterial chemoembolization (TACE) with hepatic infusion of @entity4 and @entity8 and @entity11 chemoembolization in large @entity1 ( @entity1 ). METHODS: In this retrospective study, 132 @entity0 with unresectable HCCs larger than 10 cm were treated with hepatic infusion of @entity4 and @entity8 followed by @entity11 chemoembolization. The primary endpoint was @entity7 ( @entity7 ). Sixteen-week disease-control rate, @entity5 ( @entity5 ), and major complications were also studied. Univariate and multivariate analyses were performed to identify prognostic factors affecting @entity7 and @entity5 . RESULTS: A total of 319 procedures were performed in the 132 @entity0 . Eleven (8.3%) @entity0 received radical resection following TACE treatment (median time to initial TACE 4.3    2.3 mo). The median @entity7 and @entity5 were 10.3 and 3.0 mo respectively, with a 50.0% 16-wk disease-control rate. Major complications were encountered in 6.0% (8/132) of @entity0 following TACE and included serious @entity6 in 1.5% (2/132) @entity0 , @entity10 in 1.5% (2/132), and @entity9 in 3.0% (4/132). One @entity0 died within one month due to serious @entity9 and @entity3 after receiving the second TACE. The risk factor associated with @entity5 was baseline @entity2 level, and vascular invasion was an independent factor related to @entity7 . CONCLUSION: Hepatic infusion of @entity4 and @entity8 followed by lipiodolized-chemoembolization is a safe and promising treatment for @entity0 with HCCs larger than 10 cm in diameter.

title: @entity4 and XXXX hepatic infusion with lipiodolized chemoembolization in large @entity1 .

answer: @entity8


abstract: AIM: To investigate transarterial chemoembolization (TACE) with hepatic infusion of @entity4 and @entity8 and @entity11 chemoembolization in large @entity1 ( @entity1 ). METHODS: In this retrospective study, 132 @entity0 with unresectable HCCs larger than 10 cm were treated with hepatic infusion of @entity4 and @entity8 followed by @entity11 chemoembolization. The primary endpoint was @entity7 ( @entity7 ). Sixteen-week disease-control rate, @entity5 ( @entity5 ), and major complications were also studied. Univariate and multivariate analyses were performed to identify prognostic factors affecting @entity7 and @entity5 . RESULTS: A total of 319 procedures were performed in the 132 @entity0 . Eleven (8.3%) @entity0 received radical resection following TACE treatment (median time to initial TACE 4.3    2.3 mo). The median @entity7 and @entity5 were 10.3 and 3.0 mo respectively, with a 50.0% 16-wk disease-control rate. Major complications were encountered in 6.0% (8/132) of @entity0 following TACE and included serious @entity6 in 1.5% (2/132) @entity0 , @entity10 in 1.5% (2/132), and @entity9 in 3.0% (4/132). One @entity0 died within one month due to serious @entity9 and @entity3 after receiving the second TACE. The risk factor associated with @entity5 was baseline @entity2 level, and vascular invasion was an independent factor related to @entity7 . CONCLUSION: Hepatic infusion of @entity4 and @entity8 followed by lipiodolized-chemoembolization is a safe and promising treatment for @entity0 with HCCs larger than 10 cm in diameter.

title: @entity4 and @entity8 hepatic infusion with lipiodolized chemoembolization in large XXXX .

answer: @entity1


abstract: In an open study, 30 @entity0 with clue cell-positive discharge (CCPD) were treated for seven days with either @entity1 , @entity1 - @entity2 or @entity3 (ten in each group). @entity0 were monitored on days 2, 4, 9 and 15. Clinical and microscopical parameters were used to assess treatment efficacy. Gas-liquid chromatography of vaginal secretions was also performed. The succinate- @entity4 ratio had good correlation with the clinical findings. All @entity0 treated with @entity3 were cured by day 4, suggesting that a three-day course is as effective as the standard seven-day regimen. Treatment with @entity1 - @entity2 was less effective resulting in the cure of seven @entity0 by day 15. @entity1 established normal secretions in only four @entity0 . Gastro-intestinal complaints, although common in @entity0 treated with @entity1 - @entity2 , were generally mild. We consider @entity1 - @entity2 a possible alternative in the treatment of CCPD.

title: @entity1 , @entity1 - XXXX and @entity3 in the treatment of clue cell-positive discharge. A comparative clinical and laboratory study.

answer: @entity2


abstract: In an open study, 30 @entity0 with clue cell-positive discharge (CCPD) were treated for seven days with either @entity1 , @entity1 - @entity2 or @entity3 (ten in each group). @entity0 were monitored on days 2, 4, 9 and 15. Clinical and microscopical parameters were used to assess treatment efficacy. Gas-liquid chromatography of vaginal secretions was also performed. The succinate- @entity4 ratio had good correlation with the clinical findings. All @entity0 treated with @entity3 were cured by day 4, suggesting that a three-day course is as effective as the standard seven-day regimen. Treatment with @entity1 - @entity2 was less effective resulting in the cure of seven @entity0 by day 15. @entity1 established normal secretions in only four @entity0 . Gastro-intestinal complaints, although common in @entity0 treated with @entity1 - @entity2 , were generally mild. We consider @entity1 - @entity2 a possible alternative in the treatment of CCPD.

title: XXXX , @entity1 - @entity2 and @entity3 in the treatment of clue cell-positive discharge. A comparative clinical and laboratory study.

answer: @entity1


abstract: In an open study, 30 @entity0 with clue cell-positive discharge (CCPD) were treated for seven days with either @entity1 , @entity1 - @entity2 or @entity3 (ten in each group). @entity0 were monitored on days 2, 4, 9 and 15. Clinical and microscopical parameters were used to assess treatment efficacy. Gas-liquid chromatography of vaginal secretions was also performed. The succinate- @entity4 ratio had good correlation with the clinical findings. All @entity0 treated with @entity3 were cured by day 4, suggesting that a three-day course is as effective as the standard seven-day regimen. Treatment with @entity1 - @entity2 was less effective resulting in the cure of seven @entity0 by day 15. @entity1 established normal secretions in only four @entity0 . Gastro-intestinal complaints, although common in @entity0 treated with @entity1 - @entity2 , were generally mild. We consider @entity1 - @entity2 a possible alternative in the treatment of CCPD.

title: @entity1 , XXXX - @entity2 and @entity3 in the treatment of clue cell-positive discharge. A comparative clinical and laboratory study.

answer: @entity1


abstract: In an open study, 30 @entity0 with clue cell-positive discharge (CCPD) were treated for seven days with either @entity1 , @entity1 - @entity2 or @entity3 (ten in each group). @entity0 were monitored on days 2, 4, 9 and 15. Clinical and microscopical parameters were used to assess treatment efficacy. Gas-liquid chromatography of vaginal secretions was also performed. The succinate- @entity4 ratio had good correlation with the clinical findings. All @entity0 treated with @entity3 were cured by day 4, suggesting that a three-day course is as effective as the standard seven-day regimen. Treatment with @entity1 - @entity2 was less effective resulting in the cure of seven @entity0 by day 15. @entity1 established normal secretions in only four @entity0 . Gastro-intestinal complaints, although common in @entity0 treated with @entity1 - @entity2 , were generally mild. We consider @entity1 - @entity2 a possible alternative in the treatment of CCPD.

title: @entity1 , @entity1 - @entity2 and XXXX in the treatment of clue cell-positive discharge. A comparative clinical and laboratory study.

answer: @entity3


abstract: INTRODUCTION: Advanced video technology is available for sleep-laboratories. However, low-cost equipment for screening in the home setting has not been identified and tested, nor has a methodology for analysis of video recordings been suggested. METHODS: We investigated different combinations of hardware/software for home-videosomnography (HVS) and established a process for qualitative and quantitative analysis of HVS-recordings. A case vignette (HVS analysis for a 5.5-year-old @entity0 with major @entity1 and several co-morbidities) demonstrates how methodological considerations were addressed and how HVS added value to clinical assessment. RESULTS: We suggest an "ideal set of hardware/software" that is reliable, affordable (    500) and portable (=2.8   kg) to conduct non-invasive HVS, which allows time-lapse analyses. The equipment consists of a net-book, a camera with infrared optics, and a video capture device. (1) We present an HVS-analysis protocol consisting of three steps of analysis at varying replay speeds: (a) basic overview and classification at 16* normal speed; (b) second viewing and detailed descriptions at 4-8* normal speed, and (c) viewing, listening, and in-depth descriptions at real-time speed. (2) We also present a custom software program that facilitates video analysis and note-taking (Annotator(  )), and Optical Flow software that automatically quantifies movement for internal quality control of the HVS-recording. The case vignette demonstrates how the HVS-recordings revealed the dimension of @entity1 caused by @entity3 , and illustrated the cascade of symptoms, @entity2 , and resulting medications. CONCLUSION: The strategy of using HVS, although requiring validation and reliability testing, opens the floor for a new "observational sleep medicine," which has been useful in describing discomfort-related behavioral movement patterns in @entity0 with communication difficulties presenting with challenging/disruptive sleep/wake behaviors.

title: "Diagnosis by behavioral observation" home-videosomnography - a rigorous ethnographic approach to sleep of XXXX with neurodevelopmental conditions.

answer: @entity0


abstract: BACKGROUND: Understanding how urbanisation and rural-urban migration influence risk-factors for @entity3 ( @entity3 ) is crucial for developing effective preventative strategies globally. This study compares @entity3 risk-factor prevalence in urban, rural and migrant populations in China, Ghana, India, Mexico, Russia and South Africa. METHODS: Study @entity0 were 39,436 adults within the WHO Study on global AGEing and adult health ( @entity5 ), surveyed 2007-2010. Risk ratios (RR) for each risk-factor were calculated using logistic regression in country-specific and all country pooled analyses, adjusted for age, sex and survey design. Fully adjusted models included income quintile, marital status and education. RESULTS: Regular @entity4 consumption was lower in migrant and urban groups than in rural groups (pooled RR and 95%CI: 0.47 (0.31-0.68); 0.58, (0.46-0.72), respectively). Occupational physical activity was lower (0.86 (0.72-0.98); 0.76 (0.65-0.85)) while active travel and recreational physical activity were higher (pooled RRs for urban groups; 1.05 (1.00-1.09), 2.36 (1.95-2.83), respectively; for migrant groups: 1.07 (1.0 -1.12), 1.71 (1.11-2.53), respectively). Overweight, raised waist circumference and diagnosed @entity1 were higher in urban groups (1.19 (1.04-1.35), 1.24 (1.07-1.42), 1.69 (1.15-2.47), respectively). Exceptions to these trends exist: @entity2 indicators were higher in rural Russia; active travel was lower in urban groups in Ghana and India; and in South Africa, urban groups had the highest @entity4 consumption. CONCLUSION: Migrants and urban dwellers had similar @entity3 risk-factor profiles. These were not consistently worse than those seen in rural dwellers. The variable impact of urbanisation on @entity3 risk must be considered in the design and evaluation of strategies to reduce the growing burden of NCDs globally.

title: Rural, Urban and Migrant Differences in Non-Communicable Disease Risk-Factors in Middle Income Countries: A Cross-Sectional Study of WHO- XXXX Data.

answer: @entity5


abstract: BACKGROUND: Identifying @entity2 early, commencing appropriate empiric antibiotic not only helps gain control early, but also reduces mortality and morbidity. Conventional cultures take about 5 days to identify @entity2 . To identify the @entity2 early biomarker like serum procalcitonin (SPC). AIMS: We studied the correlation of an elevated level of SPC and positive culture in elective adult @entity0 undergoing cardiac surgery. METHODS: This prospective study was conducted from January to December 2013. SPC was checked in @entity0 showing evidence of @entity3 . Simultaneously, relevant culture was also undertaken. Correlation, specificity, and sensitivity of elevated SPC were checked. RESULTS: A total of 819 adult @entity0 were included in the study. 43 of them had signs of @entity2 and SPC levels were checked. Based on the level of SPC criteria, 10 @entity0 were diagnosed as "nil", out of them, 4 had culture-positive @entity2 , 17 were suggested to have "mild @entity2 ," 3 out those had culture positivity. None among the eleven @entity0 suggested to have "moderate @entity2 ," had a positive culture, and one among the five suggested to have a severe @entity2 had a positive culture. The sensitivity was 50% and the specificity 17%. The positive predictive value was 12% and the negative predictive value 60%. CONCLUSIONS: We failed to elicit positive correlation between elevated SPC levels and @entity1 in cardio surgical @entity0 .

title: Elevated postoperative serum procalcitonin is not indicative of bacterial infection in cardiac surgical XXXX .

answer: @entity0


abstract: As a subfamily of matrix metalloproteinases (MMPs), gelatinases including @entity6 and @entity4 play an important role in remodeling and homeostasis of the extracellular matrix. However, conflicting results have been reported regarding their expression level and activity in the @entity0 kidney. This study investigated whether and how @entity4 expression and activity were changed in glomerular epithelial cells upon @entity7 overload. In situ zymography, immunostaining and Western blot for renal MMP gelatinolytic activity and @entity4 protein expression were performed in Zucker lean and Zucker @entity0 @entity1 . Confocal microscopy revealed a focal increase in gelatinase activity and @entity4 protein in the glomeruli of @entity0 @entity1 . Increased glomerular @entity4 staining was mainly observed in hyperplastic parietal epithelial cells (PECs) expressing @entity8 in the @entity0 kidneys. Interestingly, increased parietal @entity4 was often accompanied by decreased staining for podocyte markers (nephrin and @entity9 ) in the @entity3 area of affected glomeruli in @entity0 @entity1 . Additionally, urinary excretion of podocyte marker proteins was significantly increased in association with the levels of @entity4 and @entity7 in the urine of @entity0 animals. To evaluate the direct effect of @entity7 on expression and activity of @entity4 , primary cultured @entity1 glomerular PECs were incubated with rat serum @entity7 (0.25 - 1 mg/ml) for 24 - 48 hrs. @entity4 mRNA levels were significantly increased following @entity7 treatment. Meanwhile, @entity7 administration resulted in a dose-dependent increase in @entity4 protein and activity in culture supernatants of PECs. Moreover, @entity7 activated @entity5 /42 mitogen-activated protein kinase (MAPK) in PECs. Inhibition of @entity5 /42 MAPK suppressed @entity7 -induced @entity4 secretion from glomerular PECs. Taken together, we have demonstrated that an up-regulation of @entity4 in activated parietal epithelium is associated with a loss of adjacent podocytes in progressive @entity2 . @entity7 overload may induce @entity4 expression and secretion by PECs via the activation of @entity5 /42 MAPK pathway.

title: Matrix metalloproteinase-9 expression is enhanced in renal parietal epithelial cells of zucker XXXX Fatty @entity1 and is induced by @entity7 in in vitro primary parietal cell culture.

answer: @entity0


abstract: As a subfamily of matrix metalloproteinases (MMPs), gelatinases including @entity6 and @entity4 play an important role in remodeling and homeostasis of the extracellular matrix. However, conflicting results have been reported regarding their expression level and activity in the @entity0 kidney. This study investigated whether and how @entity4 expression and activity were changed in glomerular epithelial cells upon @entity7 overload. In situ zymography, immunostaining and Western blot for renal MMP gelatinolytic activity and @entity4 protein expression were performed in Zucker lean and Zucker @entity0 @entity1 . Confocal microscopy revealed a focal increase in gelatinase activity and @entity4 protein in the glomeruli of @entity0 @entity1 . Increased glomerular @entity4 staining was mainly observed in hyperplastic parietal epithelial cells (PECs) expressing @entity8 in the @entity0 kidneys. Interestingly, increased parietal @entity4 was often accompanied by decreased staining for podocyte markers (nephrin and @entity9 ) in the @entity3 area of affected glomeruli in @entity0 @entity1 . Additionally, urinary excretion of podocyte marker proteins was significantly increased in association with the levels of @entity4 and @entity7 in the urine of @entity0 animals. To evaluate the direct effect of @entity7 on expression and activity of @entity4 , primary cultured @entity1 glomerular PECs were incubated with rat serum @entity7 (0.25 - 1 mg/ml) for 24 - 48 hrs. @entity4 mRNA levels were significantly increased following @entity7 treatment. Meanwhile, @entity7 administration resulted in a dose-dependent increase in @entity4 protein and activity in culture supernatants of PECs. Moreover, @entity7 activated @entity5 /42 mitogen-activated protein kinase (MAPK) in PECs. Inhibition of @entity5 /42 MAPK suppressed @entity7 -induced @entity4 secretion from glomerular PECs. Taken together, we have demonstrated that an up-regulation of @entity4 in activated parietal epithelium is associated with a loss of adjacent podocytes in progressive @entity2 . @entity7 overload may induce @entity4 expression and secretion by PECs via the activation of @entity5 /42 MAPK pathway.

title: Matrix metalloproteinase-9 expression is enhanced in renal parietal epithelial cells of zucker @entity0 Fatty @entity1 and is induced by XXXX in in vitro primary parietal cell culture.

answer: @entity7


abstract: As a subfamily of matrix metalloproteinases (MMPs), gelatinases including @entity6 and @entity4 play an important role in remodeling and homeostasis of the extracellular matrix. However, conflicting results have been reported regarding their expression level and activity in the @entity0 kidney. This study investigated whether and how @entity4 expression and activity were changed in glomerular epithelial cells upon @entity7 overload. In situ zymography, immunostaining and Western blot for renal MMP gelatinolytic activity and @entity4 protein expression were performed in Zucker lean and Zucker @entity0 @entity1 . Confocal microscopy revealed a focal increase in gelatinase activity and @entity4 protein in the glomeruli of @entity0 @entity1 . Increased glomerular @entity4 staining was mainly observed in hyperplastic parietal epithelial cells (PECs) expressing @entity8 in the @entity0 kidneys. Interestingly, increased parietal @entity4 was often accompanied by decreased staining for podocyte markers (nephrin and @entity9 ) in the @entity3 area of affected glomeruli in @entity0 @entity1 . Additionally, urinary excretion of podocyte marker proteins was significantly increased in association with the levels of @entity4 and @entity7 in the urine of @entity0 animals. To evaluate the direct effect of @entity7 on expression and activity of @entity4 , primary cultured @entity1 glomerular PECs were incubated with rat serum @entity7 (0.25 - 1 mg/ml) for 24 - 48 hrs. @entity4 mRNA levels were significantly increased following @entity7 treatment. Meanwhile, @entity7 administration resulted in a dose-dependent increase in @entity4 protein and activity in culture supernatants of PECs. Moreover, @entity7 activated @entity5 /42 mitogen-activated protein kinase (MAPK) in PECs. Inhibition of @entity5 /42 MAPK suppressed @entity7 -induced @entity4 secretion from glomerular PECs. Taken together, we have demonstrated that an up-regulation of @entity4 in activated parietal epithelium is associated with a loss of adjacent podocytes in progressive @entity2 . @entity7 overload may induce @entity4 expression and secretion by PECs via the activation of @entity5 /42 MAPK pathway.

title: Matrix metalloproteinase-9 expression is enhanced in renal parietal epithelial cells of zucker @entity0 Fatty XXXX and is induced by @entity7 in in vitro primary parietal cell culture.

answer: @entity1


abstract: A program of sexual rehabilitation in a @entity1 center evaluated 308 @entity0 and 76 @entity0 , using a structured interview. The site of the @entity1 was pelvic or genital in 79% of @entity0 and 58% of @entity0 . Most @entity0 (73%) had one or two sessions of sexual counseling, but therapy was more intensive for about a quarter of @entity0 . Partners were included in counseling by 28% of @entity0 and 56% of @entity0 . Although @entity1 @entity0 and spouses of @entity0 reported similar rates of @entity2 before @entity1 diagnosis, after @entity1 treatment husbands and wives of @entity0 maintained stable sexual function, while dysfunctions increased dramatically in all categories except @entity6 for @entity0 . @entity0 who were older or had @entity4 were more likely to develop arousal-phase @entity2 . Psychological distress was correlated with rates of @entity3 and @entity5 in both @entity0 and @entity0 . The success of treatment in reversing @entity2 was rated by the therapist in 118 cases. @entity0 who were younger, who were not clinically depressed, and who had less conflicted marriages had more positive outcomes. Good outcome was also associated with a longer duration of treatment.

title: Sexual rehabilitation in a XXXX center: diagnosis and outcome in 384 consultations.

answer: @entity1


abstract: UNASSIGNED: Treatment of carriers of the @entity6 *2 allele and @entity3 TT genotype with clopidogrel is associated with @entity1 after percutaneous coronary intervention (PCI). We sought to evaluate a pharmacogenomic strategy among @entity0 undergoing PCI for @entity2 ( @entity2 ), by performing a randomized trial, enrolling 102 @entity0 . Point-of-care genetic testing for @entity6 *2, @entity3 TT and @entity6 *17 was performed with carriers of either the @entity6 *2 allele or @entity3 TT genotype randomly assigned to a strategy of prasugrel 10   mg daily or an augmented dosing strategy of clopidogrel (150   mg daily for 6 days then 75   mg daily). The primary end point was the proportion of at-risk carriers exhibiting @entity4 ( @entity4 ), a marker associated with increased adverse cardiovascular events, after 1 month. Fifty-nine subjects (57.8%) were identified as carriers of at least one at-risk variant. Treatment with prasugrel significantly reduced @entity4 compared with clopidogrel by @entity5 reaction unit (PRU) thresholds of >234 (0 vs 24.1%, P=0.0046) and PRU>208 (3.3 vs 34.5%, P=0.0025). The sensitivity of point-of-care testing was 100% (95% CI 88.0-100), 100% (86.3-100) and 96.9% (82.0-99.8) and specificity was 97.0% (88.5-99.5), 97.1% (89.0-99.5) and 98.5% (90.9-99.9) for identifying @entity6 *2, @entity3 TT and @entity6 *17, respectively. Logistic regression confirmed carriers as a strong predictor of @entity4 (OR=6.58, 95% CI 1.24-34.92; P=0.03). We confirmed that concurrent identification of three separate genetic variants in @entity0 with @entity2 receiving PCI is feasible at the bedside. Among carriers of at-risk genotypes, treatment with prasugrel was superior to an augmented dosing strategy of clopidogrel in reducing @entity4 .The Pharmacogenomics Journal advance online publication, 7 April 2015; doi:10.1038/tpj.2015.17.

title: A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among @entity0 with @entity2 : the RAPID XXXX study.

answer: @entity2


abstract: UNASSIGNED: Treatment of carriers of the @entity6 *2 allele and @entity3 TT genotype with clopidogrel is associated with @entity1 after percutaneous coronary intervention (PCI). We sought to evaluate a pharmacogenomic strategy among @entity0 undergoing PCI for @entity2 ( @entity2 ), by performing a randomized trial, enrolling 102 @entity0 . Point-of-care genetic testing for @entity6 *2, @entity3 TT and @entity6 *17 was performed with carriers of either the @entity6 *2 allele or @entity3 TT genotype randomly assigned to a strategy of prasugrel 10   mg daily or an augmented dosing strategy of clopidogrel (150   mg daily for 6 days then 75   mg daily). The primary end point was the proportion of at-risk carriers exhibiting @entity4 ( @entity4 ), a marker associated with increased adverse cardiovascular events, after 1 month. Fifty-nine subjects (57.8%) were identified as carriers of at least one at-risk variant. Treatment with prasugrel significantly reduced @entity4 compared with clopidogrel by @entity5 reaction unit (PRU) thresholds of >234 (0 vs 24.1%, P=0.0046) and PRU>208 (3.3 vs 34.5%, P=0.0025). The sensitivity of point-of-care testing was 100% (95% CI 88.0-100), 100% (86.3-100) and 96.9% (82.0-99.8) and specificity was 97.0% (88.5-99.5), 97.1% (89.0-99.5) and 98.5% (90.9-99.9) for identifying @entity6 *2, @entity3 TT and @entity6 *17, respectively. Logistic regression confirmed carriers as a strong predictor of @entity4 (OR=6.58, 95% CI 1.24-34.92; P=0.03). We confirmed that concurrent identification of three separate genetic variants in @entity0 with @entity2 receiving PCI is feasible at the bedside. Among carriers of at-risk genotypes, treatment with prasugrel was superior to an augmented dosing strategy of clopidogrel in reducing @entity4 .The Pharmacogenomics Journal advance online publication, 7 April 2015; doi:10.1038/tpj.2015.17.

title: A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among @entity0 with XXXX : the RAPID @entity2 study.

answer: @entity2


abstract: UNASSIGNED: Treatment of carriers of the @entity6 *2 allele and @entity3 TT genotype with clopidogrel is associated with @entity1 after percutaneous coronary intervention (PCI). We sought to evaluate a pharmacogenomic strategy among @entity0 undergoing PCI for @entity2 ( @entity2 ), by performing a randomized trial, enrolling 102 @entity0 . Point-of-care genetic testing for @entity6 *2, @entity3 TT and @entity6 *17 was performed with carriers of either the @entity6 *2 allele or @entity3 TT genotype randomly assigned to a strategy of prasugrel 10   mg daily or an augmented dosing strategy of clopidogrel (150   mg daily for 6 days then 75   mg daily). The primary end point was the proportion of at-risk carriers exhibiting @entity4 ( @entity4 ), a marker associated with increased adverse cardiovascular events, after 1 month. Fifty-nine subjects (57.8%) were identified as carriers of at least one at-risk variant. Treatment with prasugrel significantly reduced @entity4 compared with clopidogrel by @entity5 reaction unit (PRU) thresholds of >234 (0 vs 24.1%, P=0.0046) and PRU>208 (3.3 vs 34.5%, P=0.0025). The sensitivity of point-of-care testing was 100% (95% CI 88.0-100), 100% (86.3-100) and 96.9% (82.0-99.8) and specificity was 97.0% (88.5-99.5), 97.1% (89.0-99.5) and 98.5% (90.9-99.9) for identifying @entity6 *2, @entity3 TT and @entity6 *17, respectively. Logistic regression confirmed carriers as a strong predictor of @entity4 (OR=6.58, 95% CI 1.24-34.92; P=0.03). We confirmed that concurrent identification of three separate genetic variants in @entity0 with @entity2 receiving PCI is feasible at the bedside. Among carriers of at-risk genotypes, treatment with prasugrel was superior to an augmented dosing strategy of clopidogrel in reducing @entity4 .The Pharmacogenomics Journal advance online publication, 7 April 2015; doi:10.1038/tpj.2015.17.

title: A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among XXXX with @entity2 : the RAPID @entity2 study.

answer: @entity0


abstract: PURPOSE: Proximal humerus is a common site for @entity5 and frequently associated with @entity1 that limits shoulder abduction. A prospective study was conducted to evaluate the use of intramedullary non-vascularised autogenous fibular strut graft for reconstruction without internal fixation. METHODS: A total of 20 @entity0 (12 @entity0 , 8 @entity0 ) were managed for proximal humeral @entity5 with @entity1 by extended curettage, osteotomy, intramedullary fibular graft and composite bone substitute. Their ages ranged from 10 to 17  years (average, 13.3  years). The lesion was juxtaphyseal in 16 @entity0 and metaphyseal in 4. All cysts were active and centrally located type 2. The modified Enneking scoring system was used for final functional evaluation. Radiological assessment was done for the extent of defect healing, incorporation of the fibula and correction of the deformity. RESULTS: After a mean follow-up of 41.2  months (range, 24-74) most of @entity0 were satisfied and resumed daily activities without @entity2 and with good range of shoulder movement. One @entity0 complained of shoulder @entity2 10  months after surgery and was attributed to local recurrence. Limitation of recreational activity was experienced by one @entity0 . There were no cases of @entity4 or pathological @entity3 . No cases of failed healing or incorporation of the fibula was detected. The improved shoulder abduction was closely related to the mean correction of the neck shaft angle. CONCLUSIONS: The technique is proved to be effective in controlling disease, @entity1 and improving function.

title: Fibular strut graft for humeral aneurysmal bone cyst with XXXX .

answer: @entity1


abstract: BACKGROUND: Disease and therapy cause @entity3 and subsequent functional loss in pediatric @entity0 with @entity10 . Treatment-related @entity4 factors are resection in @entity0 with @entity5 ( @entity5 ) and, additionally, cranio-spinal irradiation together with chemotherapy in @entity0 with @entity9 ( @entity9 ). We tested whether damage to white matter (WM) as revealed by diffusion tensor MR imaging (DTI) correlated with specific @entity2 in survivors of pediatric @entity10 . PROCEDURES: Eighteen @entity9 (mean age        SD, 15.2        4.9 y) and 14 @entity5 (12.6        5.0 y) survivors were investigated with DTI on a 3-Tesla-MR system. We identified fractional anisotropy (FA) of WM, the volume ratio of WM to gray matter and cerebrospinal fluid (WM/ @entity8 ), and volume of specific frontocerebellar tracts. @entity6 was assessed using the International Cooperative @entity6 Rating Scale (ICARS), while the Wechsler Intelligence Scale for @entity0 determined @entity7 ( @entity7 ). Amsterdam Neuropsychological Tasks (ANT) was used to assess processing speed. Handwriting automation was analyzed using a digitizing graphic tablet. RESULTS: The WM/GM   +   @entity8 ratio correlated significantly with cognitive measures (IQ, P   =   0.002; ANT baseline speed, P   =   0.04; ANT shifting attention, P   =   0.004). FA of skeletonized tracts correlated significantly with @entity7 (P   =   0.008), ANT baseline speed (P   =   0.028) and ANT shifting attention (P   =   0.045). Moreover, frontocerebellar tract volumes correlated with both the @entity7 (P   =   0.011) and ICARS (P   =   0.007). CONCLUSION: DTI provides a method for quantification of WM damage by @entity1 and by therapy-associated effects in survivors of pediatric @entity10 . DTI-derived WM integrity may be a representative marker for @entity2 . Pediatr @entity1    2015 Wiley Periodicals, Inc.

title: Cerebral white matter fractional anisotropy and tract volume as measured by MR imaging are associated with impaired cognitive and motor function in pediatric posterior fossa XXXX survivors.

answer: @entity1


abstract: STUDY OBJECTIVE: @entity3 ( @entity3 ) is a disorder without definite consensus on its diagnosis and management during adolescence. According to Amsterdam-2012 consensus, as physiological characteristics of adolescence may overlap with @entity3 signs, it has been indicated that all Rotterdam criteria should be met. In this present study, characteristics of adolescents with different phenotypes who were diagnosed with @entity3 were evaluated; and presence of differences for metabolic risk factors between phenotypes were investigated. DESIGN: The study was performed on adolescent females. According to phenotypic application models, individuals with all Rotterdam diagnostic criteria [ @entity2 ( @entity2 ), polycystic ovarian morphology (PCOM), and chronic anovulation (CA) on the ultrasonography] were in Group 1 (n  =  26); with @entity2 and CA were in Group 2 (n  =  10); with @entity2 and PCOM were in Group 3 (n  =  7); and with CA and PCOM were in Group 4 (n  =  10). RESULTS: The most common application complaint (87%) among 53 cases enrolled in the study was @entity1 , and 57% of cases were not obese. When @entity3 was evaluated according to phenotypes, it was realized that cases that meet  all 3 diagnostic Rotterdam criteria according to the current recommendation in adolescents. (Group 1) was the most common phenotype. @entity2 was associated with more @entity0 . CONCLUSION: The close monitoring of adolescents, who have 2 diagnostic criteria is advisable among @entity3 phenotypes. Potentially Groups 2 and 3 which have @entity2 , in particular should warrant closer follow-up although they do not meet current diagnostic criteria for adolescents.

title: Diagnostic Characteristics and Metabolic Risk Factors of Cases with XXXX during Adolescence.

answer: @entity3


abstract: BACKGROUND: The aim of the present study was to assess a novel autologous cartilage plug technique used to treat anal @entity2 in ten @entity0 . METHODS: All ten @entity0 had undergone at least two prior operations for recurrent @entity2 . The plugs were prepared using the @entity0 ' own cartilage, which was obtained from either the nose or the ear, diced into pieces, and wrapped with oxidized regenerated cellulose. During the same session, @entity2 tracts were curetted using cytology brushes, and then, the cartilage plug was inserted into the tract. Routine postoperative examinations were performed at 2, 4, 8, 12, and 24  weeks after surgery. Magnetic resonance imaging was performed before surgery and at 3 and 6  months postoperatively. Relief of symptoms, radiological healing, recurrence, and continence were evaluated. RESULTS: The ten @entity0 included six males and four females, with a median age of 39  years (range 25-70  years) and a median of three previous @entity2 operations (range 2-7 operations). Nine @entity0 had cryptoglandular abscess, and one @entity0 had @entity1 . The majority of the @entity0 had transsphincteric @entity2 with substantial anal sphincter involvement. The cartilage donor site was the nose for one @entity0 and the ear for nine @entity0 . The median follow-up time was 24  months (range 10-32  months). Of the ten @entity0 , nine had @entity2 treatment without any short-term complications. The @entity2 failed to heal in one @entity0 . Among the nine @entity0 whose operations were initially successful, two late recurrences were observed. CONCLUSIONS: The cartilage plug seems to be a promising alternative for anal @entity2 treatment.

title: Treatment of recurrent anal XXXX using an autologous cartilage plug: a pilot study.

answer: @entity2


abstract: The results of investigations in 50 @entity3 @entity0 with @entity2 are presented. Using intracorporeal @entity7 , Doppler duplex scanning, cardiovascular reflex testing and skin thermal threshold monitoring, the vascular and neurological components were assessed in each of three clinical groups with probable or overt @entity2 . These comprised @entity1 . Anatomical detail of the penis was well seen using these techniques. In 15 @entity0 with @entity8 , although the aetiology was predominantly neurological, six exhibited poor flow in the deep penile arteries following injection of @entity7 . This was associated with poor erections in these @entity0 , suggesting a vascular pathology. In 27 @entity0 with @entity1 the results showed a mixed pattern. @entity4 was almost universal, combined with varying degrees of @entity6 , and only three had full erections with @entity7 . Those with @entity5 (8 @entity0 ) also had a mixed picture, although some had good erections following @entity7 injection. Duplex Doppler scanning of the deep penile arteries correlated with the quality of @entity7 -induced erection. Thermal testing was a highly sensitive indicator of small nerve fibre dysfunction, possibly at an earlier stage than standard autonomic testing. A vascular component to @entity3 was shown to be common in those with @entity2 , and may alter management.

title: Results of investigation of XXXX in @entity0 with overt or probable @entity2 .

answer: @entity3


abstract: The results of investigations in 50 @entity3 @entity0 with @entity2 are presented. Using intracorporeal @entity7 , Doppler duplex scanning, cardiovascular reflex testing and skin thermal threshold monitoring, the vascular and neurological components were assessed in each of three clinical groups with probable or overt @entity2 . These comprised @entity1 . Anatomical detail of the penis was well seen using these techniques. In 15 @entity0 with @entity8 , although the aetiology was predominantly neurological, six exhibited poor flow in the deep penile arteries following injection of @entity7 . This was associated with poor erections in these @entity0 , suggesting a vascular pathology. In 27 @entity0 with @entity1 the results showed a mixed pattern. @entity4 was almost universal, combined with varying degrees of @entity6 , and only three had full erections with @entity7 . Those with @entity5 (8 @entity0 ) also had a mixed picture, although some had good erections following @entity7 injection. Duplex Doppler scanning of the deep penile arteries correlated with the quality of @entity7 -induced erection. Thermal testing was a highly sensitive indicator of small nerve fibre dysfunction, possibly at an earlier stage than standard autonomic testing. A vascular component to @entity3 was shown to be common in those with @entity2 , and may alter management.

title: Results of investigation of @entity3 in @entity0 with overt or probable XXXX .

answer: @entity2


abstract: The results of investigations in 50 @entity3 @entity0 with @entity2 are presented. Using intracorporeal @entity7 , Doppler duplex scanning, cardiovascular reflex testing and skin thermal threshold monitoring, the vascular and neurological components were assessed in each of three clinical groups with probable or overt @entity2 . These comprised @entity1 . Anatomical detail of the penis was well seen using these techniques. In 15 @entity0 with @entity8 , although the aetiology was predominantly neurological, six exhibited poor flow in the deep penile arteries following injection of @entity7 . This was associated with poor erections in these @entity0 , suggesting a vascular pathology. In 27 @entity0 with @entity1 the results showed a mixed pattern. @entity4 was almost universal, combined with varying degrees of @entity6 , and only three had full erections with @entity7 . Those with @entity5 (8 @entity0 ) also had a mixed picture, although some had good erections following @entity7 injection. Duplex Doppler scanning of the deep penile arteries correlated with the quality of @entity7 -induced erection. Thermal testing was a highly sensitive indicator of small nerve fibre dysfunction, possibly at an earlier stage than standard autonomic testing. A vascular component to @entity3 was shown to be common in those with @entity2 , and may alter management.

title: Results of investigation of @entity3 in XXXX with overt or probable @entity2 .

answer: @entity0


abstract: OBJECTIVES: To test whether str oke features relate to living standard within one city by comparing 2 districts. METHODS: District-8 (D-8) ranks the last, whereas District-12 (D-12) is the second regarding personal monthly income of the 23 districts of Budapest, Hungary. @entity1 cases hospitalized in 2007 were identified by the database of the National Health Insurance Fund and postal codes for living address. Case certification was performed by personal visits to the general practitioners. Demographic data, risk factors and survival status in 2010 were analyzed using the anonymized database. RESULTS: Three-year case fatality was 36.6  % in D-8 and 31.5  % in D-12 (p  =  0.24). Of the fatal cases, @entity0 were more than 12  years younger in D-8 than in D-12 (69.2      13.3 vs. 82.4      9.2  years, p  <  0.001). @entity0 died younger than @entity0 in D-8 (69.2      13.3 vs. 75.2      12.4; p  =  0.036), but not in D-12 (82.4      9.2 vs. 81.9      7.3, p  =  0.8). Non-treated @entity2 , @entity3 , and smoking were significantly more prevalent in the poor district (p  <  0.01 for all). CONCLUSION: In national @entity1 programs of former Eastern Block countries, primary prevention should focus especially on male populations of less wealthy regions.

title: Living standard is related to microregional differences in XXXX characteristics in Central Europe: the Budapest Districts 8-12 Project.

answer: @entity1


abstract: Treadmill exercise test performance and ambulatory heart rate and activity patterns of 40 @entity0 with @entity3 attacks were compared with 20 age-matched controls (control group 1) and 20 nonexercising controls (control group 2). All @entity0 underwent a symptom-limited exercise stress test. @entity3 @entity0 and control group 1 wore an ambulatory heart rate/activity monitor for up to 3 days. @entity3 @entity0 had a significantly higher heart rate at 4 and 6 METS than either control group. The max METS were 11.2 +/- 2.3, 13.5 +/- 2.3 and 11.2 +/- 1.8 for the @entity3 @entity0 and control groups 1 and 2, respectively. One @entity3 @entity0 had @entity1 on the treadmill at 12 METS. @entity3 @entity0 had a significantly higher standing heart rate than controls. Furthermore, 11 of 39 @entity3 @entity0 had @entity2 on standing compared with 3 of 40 controls. @entity3 @entity0 had higher wake and sleep heart rates than control group 1, but the differences were not significant. These results are consistent with @entity4 in @entity3 @entity0 but may also be due to differences in physical conditioning. The treadmill can be useful for reassuring @entity0 and for identifying the rare @entity0 with @entity1 on exercise.

title: Treadmill exercise test and ambulatory measures in XXXX attacks.

answer: @entity3


abstract: PURPOSE: In 2 large-scale, placebo-controlled trials, @entity4 improved both @entity2 and @entity2 interference in @entity0 with @entity1 due to @entity3 ( @entity3 ). In both trials, @entity4 found statistically significant improvement compared with placebo after 1 week of treatment. However, the effects of @entity4 in the days immediately after initiation of treatment are unknown. The purpose of the present analysis was to determine timing of @entity4 's therapeutic effect in the days after initiation of treatment. METHODS: Data were derived from 2 trials of @entity4 in @entity0 with @entity3 -related @entity1 . Each day @entity0 rated severity of @entity2 and @entity2 interference over the past 24 hours on a scale from 0 to 10, with higher scores indicating greater severity. To quantify timing of therapeutic effect, we compared ( @entity4 [vs] placebo) daily average @entity2 and @entity2 interference scores over the first 14 days of treatment. Significant improvement was defined as the first day, of >= 2 consecutive days, that @entity4 significantly (P < 0.05) reduced mean scores compared with placebo. To further quantify timing of therapeutic effect, each treatment group was examined to determine the time required to achieve a >= 1-point improvement in @entity2 and @entity2 interference score among @entity0 with a clinically meaningful and sustained response (>= 30% improvement from baseline to end point) by using a time-to-event analysis method. Kaplan-Meier analyses were used to estimate the median (or 25th quartile) time (in days) required to achieve a >= 1-point improvement, among these responders, in @entity2 and @entity2 interference scores. Comparisons between @entity4 and placebo were made with a log-rank test. FINDINGS: In both trials, significant improvement of @entity2 and @entity2 interference occurred within 2 days of initiating treatment with @entity4 . Among @entity0 reporting a clinically meaningful and sustained response to treatment ( @entity0 with >= 30% improvement from baseline to end point), the time to a >= 1-point improvement of @entity2 and @entity2 interference occurred significantly earlier among @entity4 -treated @entity0 than among placebo-treated @entity0 . Finally, the timing of @entity4 's effect on @entity2 and @entity2 interference was unaffected by the use of concomitant medications that were allowed for treatment of @entity1 in both trials. IMPLICATIONS: Treatment with @entity4 results in rapid time to significant improvement in both @entity2 and @entity2 interference in @entity0 with @entity1 due to @entity3 . These findings should only be used as a guide to physicians and @entity0 as to when clinical response to @entity4 may be expected.

title: Examining the Time to Therapeutic Effect of XXXX in @entity3 @entity0 With @entity1 .

answer: @entity4


abstract: PURPOSE: In 2 large-scale, placebo-controlled trials, @entity4 improved both @entity2 and @entity2 interference in @entity0 with @entity1 due to @entity3 ( @entity3 ). In both trials, @entity4 found statistically significant improvement compared with placebo after 1 week of treatment. However, the effects of @entity4 in the days immediately after initiation of treatment are unknown. The purpose of the present analysis was to determine timing of @entity4 's therapeutic effect in the days after initiation of treatment. METHODS: Data were derived from 2 trials of @entity4 in @entity0 with @entity3 -related @entity1 . Each day @entity0 rated severity of @entity2 and @entity2 interference over the past 24 hours on a scale from 0 to 10, with higher scores indicating greater severity. To quantify timing of therapeutic effect, we compared ( @entity4 [vs] placebo) daily average @entity2 and @entity2 interference scores over the first 14 days of treatment. Significant improvement was defined as the first day, of >= 2 consecutive days, that @entity4 significantly (P < 0.05) reduced mean scores compared with placebo. To further quantify timing of therapeutic effect, each treatment group was examined to determine the time required to achieve a >= 1-point improvement in @entity2 and @entity2 interference score among @entity0 with a clinically meaningful and sustained response (>= 30% improvement from baseline to end point) by using a time-to-event analysis method. Kaplan-Meier analyses were used to estimate the median (or 25th quartile) time (in days) required to achieve a >= 1-point improvement, among these responders, in @entity2 and @entity2 interference scores. Comparisons between @entity4 and placebo were made with a log-rank test. FINDINGS: In both trials, significant improvement of @entity2 and @entity2 interference occurred within 2 days of initiating treatment with @entity4 . Among @entity0 reporting a clinically meaningful and sustained response to treatment ( @entity0 with >= 30% improvement from baseline to end point), the time to a >= 1-point improvement of @entity2 and @entity2 interference occurred significantly earlier among @entity4 -treated @entity0 than among placebo-treated @entity0 . Finally, the timing of @entity4 's effect on @entity2 and @entity2 interference was unaffected by the use of concomitant medications that were allowed for treatment of @entity1 in both trials. IMPLICATIONS: Treatment with @entity4 results in rapid time to significant improvement in both @entity2 and @entity2 interference in @entity0 with @entity1 due to @entity3 . These findings should only be used as a guide to physicians and @entity0 as to when clinical response to @entity4 may be expected.

title: Examining the Time to Therapeutic Effect of @entity4 in @entity3 @entity0 With XXXX .

answer: @entity1


abstract: PURPOSE: In 2 large-scale, placebo-controlled trials, @entity4 improved both @entity2 and @entity2 interference in @entity0 with @entity1 due to @entity3 ( @entity3 ). In both trials, @entity4 found statistically significant improvement compared with placebo after 1 week of treatment. However, the effects of @entity4 in the days immediately after initiation of treatment are unknown. The purpose of the present analysis was to determine timing of @entity4 's therapeutic effect in the days after initiation of treatment. METHODS: Data were derived from 2 trials of @entity4 in @entity0 with @entity3 -related @entity1 . Each day @entity0 rated severity of @entity2 and @entity2 interference over the past 24 hours on a scale from 0 to 10, with higher scores indicating greater severity. To quantify timing of therapeutic effect, we compared ( @entity4 [vs] placebo) daily average @entity2 and @entity2 interference scores over the first 14 days of treatment. Significant improvement was defined as the first day, of >= 2 consecutive days, that @entity4 significantly (P < 0.05) reduced mean scores compared with placebo. To further quantify timing of therapeutic effect, each treatment group was examined to determine the time required to achieve a >= 1-point improvement in @entity2 and @entity2 interference score among @entity0 with a clinically meaningful and sustained response (>= 30% improvement from baseline to end point) by using a time-to-event analysis method. Kaplan-Meier analyses were used to estimate the median (or 25th quartile) time (in days) required to achieve a >= 1-point improvement, among these responders, in @entity2 and @entity2 interference scores. Comparisons between @entity4 and placebo were made with a log-rank test. FINDINGS: In both trials, significant improvement of @entity2 and @entity2 interference occurred within 2 days of initiating treatment with @entity4 . Among @entity0 reporting a clinically meaningful and sustained response to treatment ( @entity0 with >= 30% improvement from baseline to end point), the time to a >= 1-point improvement of @entity2 and @entity2 interference occurred significantly earlier among @entity4 -treated @entity0 than among placebo-treated @entity0 . Finally, the timing of @entity4 's effect on @entity2 and @entity2 interference was unaffected by the use of concomitant medications that were allowed for treatment of @entity1 in both trials. IMPLICATIONS: Treatment with @entity4 results in rapid time to significant improvement in both @entity2 and @entity2 interference in @entity0 with @entity1 due to @entity3 . These findings should only be used as a guide to physicians and @entity0 as to when clinical response to @entity4 may be expected.

title: Examining the Time to Therapeutic Effect of @entity4 in XXXX @entity0 With @entity1 .

answer: @entity3


abstract: PURPOSE: In 2 large-scale, placebo-controlled trials, @entity4 improved both @entity2 and @entity2 interference in @entity0 with @entity1 due to @entity3 ( @entity3 ). In both trials, @entity4 found statistically significant improvement compared with placebo after 1 week of treatment. However, the effects of @entity4 in the days immediately after initiation of treatment are unknown. The purpose of the present analysis was to determine timing of @entity4 's therapeutic effect in the days after initiation of treatment. METHODS: Data were derived from 2 trials of @entity4 in @entity0 with @entity3 -related @entity1 . Each day @entity0 rated severity of @entity2 and @entity2 interference over the past 24 hours on a scale from 0 to 10, with higher scores indicating greater severity. To quantify timing of therapeutic effect, we compared ( @entity4 [vs] placebo) daily average @entity2 and @entity2 interference scores over the first 14 days of treatment. Significant improvement was defined as the first day, of >= 2 consecutive days, that @entity4 significantly (P < 0.05) reduced mean scores compared with placebo. To further quantify timing of therapeutic effect, each treatment group was examined to determine the time required to achieve a >= 1-point improvement in @entity2 and @entity2 interference score among @entity0 with a clinically meaningful and sustained response (>= 30% improvement from baseline to end point) by using a time-to-event analysis method. Kaplan-Meier analyses were used to estimate the median (or 25th quartile) time (in days) required to achieve a >= 1-point improvement, among these responders, in @entity2 and @entity2 interference scores. Comparisons between @entity4 and placebo were made with a log-rank test. FINDINGS: In both trials, significant improvement of @entity2 and @entity2 interference occurred within 2 days of initiating treatment with @entity4 . Among @entity0 reporting a clinically meaningful and sustained response to treatment ( @entity0 with >= 30% improvement from baseline to end point), the time to a >= 1-point improvement of @entity2 and @entity2 interference occurred significantly earlier among @entity4 -treated @entity0 than among placebo-treated @entity0 . Finally, the timing of @entity4 's effect on @entity2 and @entity2 interference was unaffected by the use of concomitant medications that were allowed for treatment of @entity1 in both trials. IMPLICATIONS: Treatment with @entity4 results in rapid time to significant improvement in both @entity2 and @entity2 interference in @entity0 with @entity1 due to @entity3 . These findings should only be used as a guide to physicians and @entity0 as to when clinical response to @entity4 may be expected.

title: Examining the Time to Therapeutic Effect of @entity4 in @entity3 XXXX With @entity1 .

answer: @entity0


abstract: UNASSIGNED: @entity4 en coup the sabre (LSCS), progressive @entity6 (PFH) and @entity7 are distinct clinical entities, although @entity0 with overlapping features have been reported. We performed a multicenter retrospective review of a series of @entity0 with LSCS and/or PFH to explore the relation between these entities. The files of 16 @entity0 were reviewed, 11 presented with LSCS, 5 with PFH, with time overlapping cutaneous features were seen. Extracutaneous signs were found in both groups. ANA were present in more than 50  % of @entity0 . Almost half of our @entity0 presented with CNS manifestations comprising @entity1 , @entity5 and @entity3 with or without abnormalities on MRI. Brain biopsy in one @entity0 was consistent with @entity2 . In two other @entity0 , associated autoimmune manifestations were present. CONCLUSION: Our @entity0 cohort brings more arguments to consider LSCS and PFH as a single disease entity with LSCS and superficial skin involvement at one end of the spectrum and PFH with involvement of subcutaneous deep tissue at the other end. In both entities, @entity2 can be observed. Our findings of circulating ANA, intradermal lymphocytes and IgG, intrathecal IgG production and clinical improvement with immunosuppressive therapy endorse the concept of a possible common immune-inflammatory pathogenesis. What is known:     LSCS, PFH and immune-inflammatory @entity2 are distinct clinical entities, but @entity0 with overlapping features have been reported. What is new:     We present a unique paediatric cohort with LSCS, PFH and/or @entity2 .     We endorse the concept of a common immune-inflammatory disease process.

title: Overlap between @entity4 , progressive @entity6 and immune-inflammatory XXXX in a paediatric cohort.

answer: @entity2


abstract: UNASSIGNED: @entity4 en coup the sabre (LSCS), progressive @entity6 (PFH) and @entity7 are distinct clinical entities, although @entity0 with overlapping features have been reported. We performed a multicenter retrospective review of a series of @entity0 with LSCS and/or PFH to explore the relation between these entities. The files of 16 @entity0 were reviewed, 11 presented with LSCS, 5 with PFH, with time overlapping cutaneous features were seen. Extracutaneous signs were found in both groups. ANA were present in more than 50  % of @entity0 . Almost half of our @entity0 presented with CNS manifestations comprising @entity1 , @entity5 and @entity3 with or without abnormalities on MRI. Brain biopsy in one @entity0 was consistent with @entity2 . In two other @entity0 , associated autoimmune manifestations were present. CONCLUSION: Our @entity0 cohort brings more arguments to consider LSCS and PFH as a single disease entity with LSCS and superficial skin involvement at one end of the spectrum and PFH with involvement of subcutaneous deep tissue at the other end. In both entities, @entity2 can be observed. Our findings of circulating ANA, intradermal lymphocytes and IgG, intrathecal IgG production and clinical improvement with immunosuppressive therapy endorse the concept of a possible common immune-inflammatory pathogenesis. What is known:     LSCS, PFH and immune-inflammatory @entity2 are distinct clinical entities, but @entity0 with overlapping features have been reported. What is new:     We present a unique paediatric cohort with LSCS, PFH and/or @entity2 .     We endorse the concept of a common immune-inflammatory disease process.

title: Overlap between XXXX , progressive @entity6 and immune-inflammatory @entity2 in a paediatric cohort.

answer: @entity4